Background {#Sec1}
==========

Depression is a worldwide public health problem \[[@CR1], [@CR2]\], and depressive disorder has become one of the leading causes of worldwide disability \[[@CR3]\], which could contribute to an increased risk of all-cause mortality \[[@CR4]\]. High prevalence of depression has been reported in patients with cardiovascular diseases (CVD) and its presence increases the risk for adverse cardiovascular events \[[@CR5]\]. However, the awareness of depressive symptoms among such population is quite low and the majority of them are not appropriately treated and controlled. Therefore, identifying all the epidemiological characteristics for depressive symptoms will help to create population-based strategies to prevent and treat this serious health problem.

In recent years, the measurement of health has been broadened beyond traditional health indicators such as mortality and morbidity. Thus, quality of life (QoL) is defined by the World Health Organization (WHO) as individuals' perceptions of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns \[[@CR6]\]. It has received growing attention recently, and can be impaired in patients with established CVD \[[@CR7]\] or in individuals at high risk of CVD \[[@CR8]\].

The CHADS~2~ score is a simple but reliable clinical scheme, which includes congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, and prior stroke or transient ischemic attack. It has been widely used to assess the risk of stroke for patients with atrial fibrillation (AF) \[[@CR9], [@CR10]\]. Moreover, the application of the CHADS~2~ score was not limited in AF population or assessing the risk of stroke in recent studies. In patients with acute coronary syndrome with or without AF, the score could be used as a risk assessment tool for mortality \[[@CR11]\]. Furthermore, the score is newly found to be associated with peripheral arterial occlusive disease in patients without AF \[[@CR12]\].

However, the association of the CHADS~2~ score with depressive symptoms and QoL has never been reported, even though the prevalence of depression has been proved to be apparently higher in heart failure \[[@CR13]\], hypertension \[[@CR14]\], diabetes \[[@CR15]\], and stroke \[[@CR16]\] than in the general population \[[@CR17]\]. Therefore, the current study was designed to explore the association between the CHADS~2~ score, depressive symptoms, and QoL in a general Chinese population.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

A representative sample of men and women ≥ 35 years of age from Liaoning Province was recruited between January 2013 and August 2013, using a multi-stage, randomly stratified, cluster-sampling scheme, which is called the Northeast China Rural Cardiovascular Health Study (NCRCHS). And our current study about CHADS~2~ score, depressive symptoms, and quality of life was part of the NCRCHS. Three counties (Dawa, Zhangwu, and Liaoyang) were selected from the eastern, southern, and northern regions of Liaoning Province. One township near a city in each county was randomly selected giving a total of three townships. Six to eight villages from each township were randomly selected to give a total of 26 rural villages. All of the eligible permanent residents aged ≥ 35 years from each village (*n* = 14,016) were invited to participate in the study, and 11,956 (response rate 85.3%) agreed to do so. Participants with pregnancy and malignant tumor were excluded from the present study. And subjects with severe mental disorders (for example psychosis) who couldn't complete the face-to-face survey of NCRCHS were also excluded.

The study was approved by the Ethics Committee of China Medical University (Shenyang, China). All procedures were performed in accordance with the ethical standards. Written consent was obtained from all participants after they had been informed of the study's objectives, benefits, medical procedures, and confidentiality safeguards for personal information. In the case of an illiterate participant, written informed consent was obtained from the appropriate legal proxy.

Data collection and measurement {#Sec4}
-------------------------------

Data were collected during a single clinic visit by doctors and trained nurses using a standard questionnaire in a face-to-face interview. All potential investigators had received training on the objectives of the study, how to administer the questionnaire, the standard methods of measurement, the importance of standardization, and study procedures. Only those who earned a perfect score on a post-training test were allowed to participate as study investigators. During data collection, the inspectors received further instructions and support.

Data on the demographic characteristics, lifestyle risk factors, family income, medical history of hypertension, congestive heart failure, stroke, diabetes mellitus, depressive symptoms, and quality of life were obtained, as described above, by interview with the standardized questionnaire. There was a central steering committee with a subcommittee for quality control that made sure all data were collected according to well-known standards.

Depressive symptoms {#Sec5}
-------------------

Depressive symptoms were assessed using the Patient Health Questionnaire-9 (PHQ-9), which was a 9-item screening instrument and widely used in primary health centers with high reliability and validity \[[@CR18], [@CR19]\]. Participants were asked how often, over the past 2 weeks, they had been bothered by each of the depressive symptoms with the score ranging from 0 to 3. Then, the total score of PHQ-9 ranged from 0 to 27. The severity of depressive disorder was considered mild for score of 5 to 9, moderate for score of 10 to 14, moderately severe for score of 15 to 19 and severe for score of 20 to 27. A PHQ-9 score ≥ 10 was recommended as the cut-off score for detecting major depressive disorders \[[@CR20]\].

Quality of life {#Sec6}
---------------

The quality of life was measured with the World Health Organization Quality of Life Brief Scale (WHOQOL-BREF), which was a self-report inventory with 26 original items \[[@CR21], [@CR22]\]. The items fell into four domains: the physical health (7 items), the psychological health (6 items), the social relationships (3 items), and the environment (8 items), together with 2 items measuring the overall QoL and general health. Each item was answered on a 5-point response scale, and the range of score for each domain was from 4 to 20 after calculation, with higher score indicating better QoL.

CHADS~2~ score {#Sec7}
--------------

The CHADS~2~ score was calculated for each subject based on the point system with 2 points for a history of stroke and 1 point for congestive heart failure, hypertension, an age ≥ 75 years and diabetes mellitus. Congestive heart failure was assigned positive if they had ever been told by a physician that they had congestive heart failure \[[@CR23]\]. Similarly, stroke was defined as a history of prior stroke or transient ischemic attack. Hypertension was defined as a systolic blood pressure (SBP) ≥ 140 mmHg and/or diastolic blood pressure (DBP) ≥ 90 mmHg and/or the use of antihypertensive medications according to the Eighth Joint National Committee on the guidelines for the management of high blood pressure in adults (JNC-8) \[[@CR24]\]. World Health Organization criteria were followed for defining diabetes mellitus (fasting blood glucose ≥ 7.0 mmol/L or 126 mg/dL, and/or being on treatment for diabetes) \[[@CR25]\].

Covariate measurements {#Sec8}
----------------------

Weight and height were measured to the nearest 0.1 kg and 0.1 cm, respectively, with the participants in lightweight clothing without shoes. The body mass index (BMI) was calculated as weight in kilograms divided by the square of the height in meters.

Fasting blood samples were collected in the morning after ≥ 8 h of fasting for all participants. Blood samples were obtained from an antecubital vein using BD Vacutainer tubes containing EDTA. Serum was subsequently isolated from whole blood, and all serum samples were frozen at −20 °C for testing at a central, certified laboratory. Fasting blood glucose (FBG), total cholesterol (TC), triglycerides (TG), high density lipid cholesterol (HDL-C), low density lipid cholesterol (LDL-C), serum uric acid, serum creatinine, and other routine blood indices were analyzed enzymatically on an auto-Analyzer. Glomerular filtration rate (GFR) was estimated using the equation originating from the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation \[[@CR26]\].

Physical activity included occupational and leisure-time physical activity, and a detailed description of these standards has been presented \[[@CR27]\]. The combination of occupational and leisure-time physical activity was therefore described as low (light levels of activity in both categories), moderate (moderate or high levels of activity in one of the categories), or high (moderate or high levels of activity in both categories).

Statistical analysis {#Sec9}
--------------------

All statistical analyses were performed using SPSS 17.0 software (SPSS Inc., Chicago, IL, USA). Differences between groups were compared using two-tailed Student's *t*-test, ANOVA or the *χ* ^2^ test as appropriate. The prevalences of depressive symptoms among different CHADS~2~ score were calculated, and the total score of WHOQOL-BREF by PHQ-9 score and CHADS~2~ score was also presented. Both univariate and multivariate logistic regression analyses were performed to estimate the crude and independent associations between each item in CHADS~2~, CHADS~2~ score, and depressive symptoms. Multivariate linear regression analysis and optimal scale regression analysis were conducted to assess the independent associations of each item in CHADS~2~ and CHADS~2~ score with WHOQOL-BREF score, respectively. *P* \< 0.05 was considered as statistically significant.

Results {#Sec10}
=======

Characteristics of the study population {#Sec11}
---------------------------------------

Of the 11,956 participants, 896 had incomplete data and were excluded from the analysis, leaving a total of 11,060 participants (5080 men and 5980 women) with a mean age of 53.9 years. The subjects with moderate or severe depressive symptoms were significantly older and had lower percentage of men than those with no or mild depressive symptoms (*P*s \< 0.001) (Table [1](#Tab1){ref-type="table"}). The subjects with moderate or severe depressive symptoms had significantly higher FBG, TG (all *P*s \< 0.05), and lower eGFR levels (*P* \< 0.001). They also had a lower percentage of alcohol drinking and smoking and lower levels of education, income, physical activity and sleep time (all *P*s \< 0.001). In addition, the subjects with moderate or severe depressive symptoms had significantly higher levels of CHADS~2~ score and lower scores of WHOQOL-BREF (all *P*s \< 0.001). However, there were no significant differences in BMI, SBP, DBP, TC, HDL-C, LDL-C, or serum uric acid between the two groups.Table 1Comparison of the characteristics of the study sampleVariableAll (*n* = 11,060)Depressive symptoms*P* valueNo or mild (*n* = 10,390)Moderate or severe (*n* = 670)Age, years53.9 ± 10.553.7 ± 10.557.1 ± 10.2\<0.001Male5080 (45.9)4898 (47.1)182 (27.2)\<0.001BMI, kg/m^2^24.8 ± 3.724.8 ± 3.724.5 ± 3.80.050SBP, mmHg141.6 ± 23.3141.5 ± 23.2143.5 ± 25.50.051DBP, mmHg82.0 ± 11.782.0 ± 11.782.2 ± 11.80.603FBG, mmol/L5.91 ± 1.625.90 ± 1.616.09 ± 1.760.006TC, mmol/L5.24 ± 1.095.23 ± 1.085.31 ± 1.180.124TG, mmol/L1.63 ± 1.471.62 ± 1.471.75 ± 1.510.030HDL-C, mmol/L1.41 ± 0.381.41 ± 0.381.40 ± 0.400.601LDL-C, mmol/L2.93 ± 0.822.92 ± 0.822.96 ± 0.890.290Serum uric acid, umol/L292 ± 85292 ± 85289 ± 900.344eGFR, ml/min/1.73 m^2^92.8 ± 15.993.1 ± 15.788.6 ± 18.3\<0.001Current smoker3886 (35.1)3693 (35.5)193 (28.8)\<0.001Current drinker2474 (22.4)2402 (23.1)72 (10.7)\<0.001Education level\<0.001  ≤ Primary school5539 (50.1)5095 (49.0)444 (66.3) Middle school4491 (40.6)4296 (41.3)195 (29.1)  ≥ High school1030 (9.3)999 (9.6)31 (4.6)Family income, CNY/year\<0.001  ≤ 50001379 (12.5)1209 (11.6)170 (25.4) 5000--20,0006025 (54.5)5655 (54.4)370 (55.2)  \> 20,0003656 (33.1)3526 (33.9)130 (19.4)Physical activity\<0.001 Low3263 (29.5)2953 (28.4)310 (46.3) Moderate7164 (64.8)6830 (65.7)334 (49.9) High633 (5.7)607 (5.8)26 (3.9)Sleep duration, h/day7.3 ± 1.77.3 ± 1.66.2 ± 2.1\<0.001Congestive heart failure102 (0.9)78 (0.8)24 (3.6)\<0.001Hypertension5623 (50.8)5234 (50.4)389 (58.1)\<0.001Age ≥ 75 years332 (3.0)297 (2.9)35 (5.2)0.001Diabetes mellitus1154 (10.4)1051 (10.1)103 (15.4)\<0.001Stroke976 (8.8)848 (8.2)128 (19.1)\<0.001CHADS~2~ score0.83 ± 0.960.80 ± 0.941.20 ± 1.25\<0.001WHOQOL-BREF domain Physical health15.1 ± 2.315.4 ± 2.111.5 ± 2.5\<0.001 Psychological14.5 ± 2.414.8 ± 2.210.7 ± 2.6\<0.001 Social relationships14.6 ± 2.114.7 ± 2.013.0 ± 2.4\<0.001 Environment13.5 ± 2.113.6 ± 2.111.7 ± 2.1\<0.001Data are expressed as mean ± standard deviation or *n* (%)*Abbreviations*: *BMI* body mass index, *CNY* China Yuan, *DBP* diastolic blood pressure, *FBG* fasting blood glucose, *eGFR* estimated glomerular filtration rate, *HDL-C* high density lipid cholesterol, *LDL-C* low density lipid cholesterol, *SBP* systolic blood pressure, *TC* total cholesterol, *TG* triglycerides, *WHOQOL-BREF* the World Health Organization Quality of Life Brief Scale

Prevalence of depressive symptoms and QoL by CHADS~2~ score {#Sec12}
-----------------------------------------------------------

The prevalence of depressive symptoms (PHQ-9 score ≥ 10) by CHADS~2~ score was summarized (Fig. [1](#Fig1){ref-type="fig"} and Table [2](#Tab2){ref-type="table"}). It was found that the percentage of subjects with depressive symptoms increased significantly with increasing CHADS~2~ score, from the lowest of 4.9% to the highest of 27.8% (*P* \< 0.001). The QoL evaluated by WHOQOL-BREF was described according to CHADS~2~ score (Table [3](#Tab3){ref-type="table"}). As a result, the mean scores for total and every domain of WHOQOL-BREF decreased significantly with increasing CHADS~2~ score (all *P*s \< 0.001). The association of CHADS~2~ score with the total score of WHOQOL-BREF stratified by depressive symptoms was also examined and presented (Fig. [2](#Fig2){ref-type="fig"}). The total score of WHOQOL-BREF decreased siginificantly with increasing CHADS~2~ score in both subgroups (*P*s \< 0.001). The lowest level of total score was found in subjects with CHADS~2~ score of 0, while the highest was in those with CHADS~2~ score of 5.Fig. 1Prevalence of depressive symptoms by *CHADS* ~*2*~ *score*. Percentage of subjects with a PHQ-9 score ≥ 10 increases with increasing CHADS~2~ score (*P* \< 0.001). *Error bars* represent standard deviation. PHQ-9: Patient Health Questionnaire-9 Table 2Logistic regression analyses for associations between CHADS~2~ score and depressive symptoms (PHQ-9 score ≥ 10)Total (*n*)Depressive symptoms *n* (%)Unadjusted modelAdjusted model 1Adjusted model 2OR (95% CI)*P* valueOR (95% CI)*P* valueOR (95% CI)*P* valueCongestive heart failure No10,958646 (5.9)111 Yes10224 (23.5)4.91 (3.09--7.81)\<0.0013.17 (1.91--5.25)\<0.0012.98 (1.79--4.96)\<0.001Hypertension No5437281 (5.2)111 Yes5623389 (6.9)1.36 (1.16--1.60)\<0.0011.15 (0.96--1.37)0.1271.04 (0.87--1.24)0.687Age ≥ 75 years No10,728635 (5.9)111 Yes33235 (10.5)1.87 (1.31--2.68)0.0011.01 (0.68--1.51)0.9571.04 (0.70--1.55)0.851Diabetes mellitus No9906567 (5.7)111 Yes1154103 (8.9)1.61 (1.30--2.01)\<0.0011.35 (1.07--1.72)0.0131.25 (0.98--1.59)0.076Stroke No10,084542 (5.4)111 Yes976128 (13.1)2.66 (2.17--3.26)\<0.0012.02 (1.62--2.53)\<0.0011.96 (1.56--2.46)\<0.001CHADS~2~ score 04888238 (4.9)11 14253229 (5.4)1.11 (0.92--1.34)0.2651.02 (0.83--1.24)0.872 2109382 (7.5)1.59 (1.22--2.06)0.0011.15 (0.87--1.53)0.329 359875 (12.5)2.80 (2.13--3.69)\<0.0011.99 (1.47--2.68)\<0.001 421041 (19.5)4.74 (3.29--6.83)\<0.0013.47 (2.29--5.25)\<0.001 5185 (27.8)7.52 (2.66--21.25)\<0.0013.94 (1.28--12.12)0.017Adjusted model 1: adjusted for gender, body mass index, total cholesterol, triglyceride, low density lipid cholesterol, high density lipid cholesterol, serum uric acid, estimated glomerular filtration rate, smoking, drinking, education, income, physical activity, and sleep time; Adjusted model 2: adjusted for factors in model 1 and other items in CHADS~2~*Abbreviations*: *CI* confidence interval, *OR* odds ratio, *PHQ-9* Patient Health Questionnaire-9 Table 3The mean score of WHOQOL-BREF based on CHADS~2~ scoreCHADS~2~ score*P* value0 (*n* = 4888)1 (*n* = 4253)2 (*n* = 1093)3 (*n* = 598)4 (*n* = 210)5 (*n* = 18)Overall Quality of life3.30 ± 0.703.28 ± 0.683.23 ± 0.733.15 ± 0.633.02 ± 0.722.94 ± 0.64\<0.001General health3.49 ± 0.823.39 ± 0.833.24 ± 0.912.95 ± 0.892.64 ± 0.852.72 ± 1.02\<0.001Domains Physical health15.5 ± 2.115.2 ± 2.214.5 ± 2.513.7 ± 2.512.5 ± 2.911.6 ± 3.1\<0.001 Psychological14.7 ± 2.414.7 ± 2.414.2 ± 2.513.6 ± 2.512.9 ± 3.012.2 ± 3.0\<0.001 Social relationships14.9 ± 2.114.7 ± 2.014.2 ± 2.213.9 ± 2.113.2 ± 2.412.6 ± 2.1\<0.001 Environment13.6 ± 2.113.5 ± 2.113.3 ± 2.213.0 ± 2.112.7 ± 2.312.5 ± 1.9\<0.001Total Score65.4 ± 8.264.8 ± 8.062.7 ± 8.960.2 ± 8.457.0 ± 9.854.6 ± 9.2\<0.001Data are expressed as mean ± standard deviation*Abbreviations*: *WHOQOL-BREF* the World Health Organization Quality of Life Brief Scale Fig. 2Total score of WHOQOL-BREF by CHADS~2~ score stratified by depressive symptoms. The total score of *WHOQOL-BREF decreases* siginificantly with *increasing CHADS* ~*2*~ *score* in both subgroups (*P*s \< 0.001). *Error bars* represent standard deviation. PHQ-9: Patient Health Questionnaire-9; WHOQOL-BREF: World Health Organization Quality of Life Brief Scale

Association between CHADS~2~ score and depressive symptoms {#Sec13}
----------------------------------------------------------

The associations between each item in CHADS~2~, CHADS~2~ score and depressive symptoms were examined by univariate and multivariate logistic regression analyses (Table [2](#Tab2){ref-type="table"}). Heart failure and stroke were independently associated with depressive symptoms after adjusting for other items in CHADS~2~ and clinical covariates, including gender, BMI, TC, TG, LDL-C, HDL-C, serum uric acid, eGFR, smoking, drinking, education, income, physical activity, and sleep time (*P*s \< 0.001). However, the associations between hypertension, age ≥ 75 years, diabetes mellitus and depressive symptoms were significant only in univariate model (*P*s ≤ 0.001) but not in multivariate model (*P*s \> 0.05). Subjects with CHADS~2~ score ≥ 3 had significantly higher independent risk of depressive symptoms than those with CHADS~2~ score = 0 after adjusting for clinical covariates (all *P*s \< 0.05).

Association between CHADS~2~ score and QoL {#Sec14}
------------------------------------------

To explore the associations between CHADS~2~ score and QoL, a multivariate linear regression analysis was conducted for each item in CHADS~2~, and optimal scale regression analysis was used for CHADS~2~ score (as ordinal variate) (Table [4](#Tab4){ref-type="table"}). Generally speaking, items in CHADS~2~ were negatively associated with scores of WHOQOL-BREF. Congestive heart failure, age ≥ 75 years, diabetes mellitus, and stroke were all independently negatively associated with the total score of WHOQOL-BREF after adjusting for gender, BMI, TC, TG, LDL-C, HDL-C, serum uric acid, eGFR, smoking, drinking, education, income, physical activity, sleep time, and other items in CHADS~2~ (all *P*s \< 0.05). Optimal scale regression analysis showed CHADS~2~ score was independently negatively associated with all scores of WHOQOL-BREF (all *P*s \< 0.001).Table 4Multivariate linear and optimal scale regression analyses for associations between CHADS~2~ score and WHOQOL-BREFOverall quality of lifeGeneral healthDomainsTotal scorePhysical healthPsychologicalSocial relationshipsEnvironmentCongestive heart failure^a^ β−0.106−0.482−1.771−1.092−0.528−0.482−4.458  *P* value0.113\<0.001\<0.001\<0.0010.0080.016\<0.001Hypertension^a^ β0.006−0.073−0.1540.061−0.0970.075−0.169  *P* value0.690\<0.001\<0.0010.1930.0180.0710.284Age ≥ 75 years^a^ β0.1150.230−0.492−0.070−0.581−0.093−0.877  *P* value0.003\<0.001\<0.0010.596\<0.0010.4260.047Diabetes mellitus^a^ β−0.039−0.190−0.368−0.307−0.160−0.132−1.198*P* value0.191\<0.001\<0.0010.0030.0720.145\<0.001Stroke^a^ β−0.091−0.377−1.192−0.809−0.469−0.384−3.298  *P* value\<0.001\<0.001\<0.001\<0.001\<0.001\<0.001\<0.001CHADS~2~ score^b^ β−0.045−0.170−0.180−0.098−0.098−0.058−0.130  *P* value\<0.001\<0.001\<0.001\<0.001\<0.001\<0.001\<0.001*Abbreviations*: *CI* confidence interval, *WHOQOL-BREF* the World Health Organization Quality of Life Brief Scale^a^by multivariate linear regression analysis adjusted for gender, body mass index, total cholesterol, triglyceride, low density lipid cholesterol, high density lipid cholesterol, serum uric acid, estimated glomerular filtration rate, smoking, drinking, education, income, physical activity, sleep time, and other items in CHADS~2~^b^by optimal scale regression analysis adjusted for all factors in model α except for items in CHADS~2~

Discussion {#Sec15}
==========

The results of this study demonstrated that the CHADS~2~ score is significantly associated with depressive symptoms and QoL in a large general population. The tools of WHOQOL-BREF and PHQ-9 were chosen to evaluate QoL and depressive symptoms, respectively. With increasing CHADS~2~ score, the prevalence of depressive symptoms (PHQ-9 score ≥ 10) increases, while the total score and every domain of WHOQOL-BREF decreases. The independent associations were still observed after adjusting for confounding risk factors.

Previous studies demonstrated that the components of CHADS~2~ score were associated with depression and poor QoL. Depression in patients with heart failure was 4--5 times that of the general population \[[@CR28]\], and QoL was greatly impaired among patients with heart failure \[[@CR29]\]. A systemic review showed that the general prevalence of depression was as high as 26.8% among hypertensive patients \[[@CR14]\], and hypertension also impaired QoL \[[@CR30]\]. Diabetes had a marked increase in depression prevalence, however, a reduction in QoL \[[@CR31]\]. Moreover, depression was a common and serious complication after stroke, affecting nearly 30% of patients at different stages \[[@CR32]\]. The possible reasons for lower QoL and depressive symptoms among these patients included having chronic diseases, being aware of them, and comprehensive treatment \[[@CR33]\]. In this current study, only heart failure and stroke were independently associated with depressive symptoms, while old age, hypertension, and diabetes mellitus had no significant independent relation. All items in CHADS~2~ except for hypertension were associated with impaired QoL. These results were somewhat consistent with previous ones. Relatively low education level, awareness, and treatment of chronic diseases in rural China may partially contribute to the differences \[[@CR34], [@CR35]\].

The scheme of the CHADS~2~ score has been used widely, and a CHADS~2~ score ≥ 2 is considered as the risk factor for stroke in AF patients. Recent study showed that patients with a CHADS~2~ score ≥ 2 was also significantly associated with peripheral arterial occlusive disease among non-AF population \[[@CR12]\]. The present study in the general population demonstrated that subjects with CHADS~2~ score ≥ 3 had significantly higher risk of depressive symptoms than those with CHADS~2~ score = 0 after adjusting for clinical covariates. Furthermore, CHADS~2~ score was negatively associated with all scores of WHOQOL-BREF. Previous study showed that depression was accompanied by poor QoL with low scores of WHOQOL-BREF \[[@CR36]\]. This study found that CHADS~2~ score was negatively associated with the total score of WHOQOL-BREF whether or not the subjects had depressive symptoms. This is the first study to reveal the associations of CHADS~2~ score with depressive symptoms and impaired QoL.

This study has several limitations. First, the current study is cross-sectional and it was not clear whether the CHADS~2~ score would predict the incidence of depressive symptoms. Second, congestive heart failure and stroke were diagnosed based on a previous history of physician-diagnosis since a large sample was involved. This approach may give rise to an unintentional bias though it had been utilized in previous studies \[[@CR23], [@CR37]\]. Third, the current study was part of NCRCHS, and subjects with severe mental disorders who couldn't complete the survey were excluded. This may have a potential bias on the results. Fourth, the relatively small sample in some subgroups may have reduced the statistical power, and further studies with larger sample were needed to confirm the results.

Conclusions {#Sec16}
===========

This is the first study to demonstrate that the CHADS~2~ score is significantly associated with depressive symptoms and impaired QoL in the general Chinese population. Much attention should also be paid to depressive symptoms and QoL among patients with high CHADS~2~ score.
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